 97-111, TLGEFLKLDRERAKN.jpg)
Survivin (BIRC5) 97-111, TLGEFLKLDRERAKN
Description
About Survivin (BIRC5) 97-111, TLGEFLKLDRERAKN
The Human Baculoviral IAP repeat-containing protein (BIRC) 5 Peptide (IEDB: 1119556) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Baculoviral IAP repeat-containing protein (BIRC) Peptide, H-TLGEFLKLDRERAKN-OH (Uniprot: O15392 aa: 97-111) from JPT is produced under strict quality control and quality management.
Survivin (BIRC5) 97-111, TLGEFLKLDRERAKN - Specifications
- Peptide sequence: H-TLGEFLKLDRERAKN-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Cancer
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Survivin (BIRC5) 97-111, TLGEFLKLDRERAKN
References:
Read References with JPT’s Antigen Peptides
Survivin (BIRC5) 97-111, TLGEFLKLDRERAKN has been described in:
Actively personalized vaccination trial for newly diagnosed glioblastoma., Nature, 2019 (PMID: 30568303)
NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma., Cancer Immunol Immunother, 2018 (PMID: 29058035)
Documentation
Documentation for Survivin (BIRC5) 97-111, TLGEFLKLDRERAKN
Properties
Properties of Survivin (BIRC5) 97-111, TLGEFLKLDRERAKN
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Cancer |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | Baculoviral IAP repeat-containing protein (BIRC) |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Survivin (BIRC5) 97-111, TLGEFLKLDRERAKN
Information | Values |
---|---|
Sequence: | H-TLGEFLKLDRERAKN-OH |
Specifications: | 15mer peptide as TFA salt |